Objective
MEDIRAD aims to enhance the scientific bases and clinical practice of radiation protection (RP) in the medical field and thereby addresses the need to understand and evaluate the health effects of low dose ionising radiation exposure from diagnostic and therapeutic imaging and from off-target effects in radiotherapy (RT).
MEDIRAD will pursue 3 major operational objectives: First, it will improve organ dose estimation and registration to inform clinical practice, optimise doses, set recommendations and provide adequate dosimetry for clinical-epidemiological studies of effects of medical radiation. Second, it aims to evaluate and understand the effects of medical exposures, focusing on the two major endpoints of public health relevance: cardiovascular effects of low to moderate doses of radiation from RT in breast cancer treatment incl. understanding of mechanisms; and long-term effects on cancer risk of low doses from CT in children. Third, it will develop science-based consensus policy recommendations for the effective protection of patients, workers and the general public.
Within the 4-year project a multi-disciplinary consortium will, in close interaction with European medical associations, MELODI and EURADOS (1), develop a tool to determine image quality to maximise optimisation of RP in medical imaging, (2) improve and develop new individual organ/anatomical structure dosimetry from chest CT, I131 administration, fluoroscopy-guided procedures, hybrid imaging, and RT for breast cancer and interlinks with image quality measures, (3) conduct epidemiological studies of consequences of RT and CT, (4) identify potential novel imaging and circulating biomarkers and mechanisms of radiation effects, (5) develop innovative risk models, (6) develop and implement for the first time a European repository of patient dose and imaging data, (7) develop science-based recommendations, and (8) introduce novel approaches to bring together the nuclear and medical sectors.
Fields of science
- medical and health scienceshealth sciencespublic healthepidemiology
- medical and health sciencesclinical medicineradiologynuclear medicine
- medical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosis
- medical and health sciencesclinical medicineoncologybreast cancer
- engineering and technologymedical engineeringdiagnostic imaging
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
1010 Wien
Austria
See on map
Participants (35)
08036 Barcelona
See on map
75006 Paris
See on map
74100 Rethimno
See on map
SW3 6JJ London
See on map
9713 GZ Groningen
See on map
92260 Fontenay Aux Roses
See on map
39106 Magdeburg
See on map
3045-093 Coimbra
See on map
462 80 Vanersborg
See on map
08034 Barcelona
See on map
91 348 Lodz
See on map
35510 Cesson Sevigne
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
55131 Mainz
See on map
1211 Geneve
See on map
85764 Neuherberg
See on map
1160 Bruxelles
See on map
9000 Gent
See on map
97080 Wurzburg
See on map
35037 Marburg
See on map
75654 Paris
See on map
1649-028 Lisbon
See on map
81675 Muenchen
See on map
00185 Roma
See on map
Participation ended
BS8 1QU Bristol
See on map
1081 HV Amsterdam
See on map
NE1 7RU Newcastle Upon Tyne
See on map
1066 CX Amsterdam
See on map
08290 Cerdanyola Del Valles
See on map
00161 Roma
See on map
4 Dublin
See on map
31052 Toulouse Cedex 3
See on map
08908 L'hospitalet Del Llobregat
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08007 Barcelona
See on map
SW7 2AZ London
See on map
16816 Neuruppin
See on map